Payment overview · 2025
General Payments
$2,123.07
99 reported records · 24 companies
Healthcare provider profile · identity verified
Mehrdad A Tafreshi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NV · NPI 1437115292
Verified facts
What the public records show
CMS Open Payments records show Mehrdad A Tafreshi, MD received $2,123.07 in general payments during 2025 across 99 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $308.72 | 14.5% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $245.53 | 11.6% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $204.81 | 9.7% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $168.69 | 8.0% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $141.64 | 6.7% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $126.75 | 6.0% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $118.33 | 5.6% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $95.51 | 4.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.04 | 3.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $71.73 | 3.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.54 | 3.4% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $58.43 | 2.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.07 | 2.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $57.78 | 2.7% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $51.62 | 2.4% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $47.59 | 2.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.34 | 1.9% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $37.68 | 1.8% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $31.25 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.78 | 1.3% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $22.71 | 1.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.35 | 0.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.78 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.40 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,080.57 | 98 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $204.81 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $197.10 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $168.69 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $168.69 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $146.52 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $127.59 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $118.33 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $110.43 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $95.51 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $92.98 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $86.89 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $71.73 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $71.54 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $62.06 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $62.06 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.40 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.40 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $58.43 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $57.78 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $51.62 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.49 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $47.59 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.75 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $31.25 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.09 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $27.16 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 105 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 136 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 105 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 41 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 278 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 96 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
40 | 28 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
136 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
96 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
278 | 54 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1419 | 391 |
| Metformin Hcl | Metformin Hcl | 728 | 228 |
| Amlodipine Besylate | Amlodipine Besylate | 682 | 213 |
| Losartan Potassium | Losartan Potassium | 584 | 172 |
| Lisinopril | Lisinopril | 489 | 137 |
| Omeprazole | Omeprazole | 450 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 93 |
| Gabapentin | Gabapentin | 353 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 342 | 102 |
| Ozempic | Semaglutide | 278 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 269 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 220 | 39 |
| Alprazolam | Alprazolam | 216 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 66 |
| Alendronate Sodium | Alendronate Sodium | 204 | 61 |
| Ezetimibe | Ezetimibe | 192 | 57 |
| Carvedilol | Carvedilol | 185 | 58 |
| Furosemide | Furosemide | 174 | 54 |
| Meloxicam | Meloxicam | 174 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 174 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 51 |
| Glimepiride | Glimepiride | 160 | 50 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 152 | 55 |
| Ibuprofen | Ibuprofen | 149 | 70 |
| Trazodone Hcl | Trazodone Hcl | 149 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 140 | 39 |
| Sertraline Hcl | Sertraline Hcl | 140 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 139 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 39 |
| Farxiga | Dapagliflozin Propanediol | 136 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 59 |
| Azithromycin | Azithromycin | 127 | 78 |
| Montelukast Sodium | Montelukast Sodium | 122 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 109 | 77 |
| Atenolol | Atenolol | 108 | 32 |
| Famotidine | Famotidine | 108 | 38 |
| Donepezil Hcl | Donepezil Hcl | 107 | 34 |
| Eliquis | Apixaban | 105 | 36 |
| Jardiance | Empagliflozin | 105 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 17 |
| Potassium Chloride | Potassium Chloride | 86 | 25 |
| Allopurinol | Allopurinol | 84 | 19 |
| Bupropion Xl | Bupropion Hcl | 74 | 26 |
| Simvastatin | Simvastatin | 73 | 18 |
| Xarelto | Rivaroxaban | 72 | 16 |
| Fenofibrate | Fenofibrate | 71 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 68 | 17 |
| Valsartan | Valsartan | 67 | 25 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 19 |
| Lorazepam | Lorazepam | 63 | 15 |
| Mounjaro | Tirzepatide | 63 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 17 |
| Finasteride | Finasteride | 54 | 18 |
| Mirtazapine | Mirtazapine | 54 | 15 |
| Clonidine Hcl | Clonidine Hcl | 53 | 16 |
| Benazepril Hcl | Benazepril Hcl | 51 | 14 |
| Prednisone | Prednisone | 51 | 28 |
| Meclizine Hcl | Meclizine Hcl | 50 | 24 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 47 | suppressed |
| Diazepam | Diazepam | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Pregabalin | Pregabalin | 45 | 12 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 43 | 23 |
| Fluconazole | Fluconazole | 43 | 20 |
| Methylprednisolone | Methylprednisolone | 43 | 30 |
| Linzess | Linaclotide | 41 | 13 |
| Ondansetron Odt | Ondansetron | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 28 |
| Prolia | Denosumab | 40 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 14 |
| Propranolol Hcl | Propranolol Hcl | 37 | 15 |
| Irbesartan | Irbesartan | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 27 |
| Mupirocin | Mupirocin | 33 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 11 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 13 |
| Methocarbamol | Methocarbamol | 30 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 21 |
| Methimazole | Methimazole | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 14 |
| Tramadol Hcl | Tramadol Hcl | 24 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | 12 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Armodafinil | Armodafinil | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | 17 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Ssd | Silver Sulfadiazine | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Verapamil Sr | Verapamil Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Temazepam | Temazepam | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,123.07 · 99 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, AREXVY, BREZTRI, CREON, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GLYCATE, JARDIANCE, KISUNLA, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NUCALA, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, QULIPTA, Quviviq, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, XYOSTED, YUPELRI, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error